Loading
Yanuki
KEYWORD TOPIC
ImmunityBio's Anktiva: Asian Expansion and NCCN Guideline Inclusion | ImmunityBio Advances NMIBC Program with Positive ANKTIVA® Data | ImmunityBio's Anktiva: Asian Expansion and NCCN Guideline Inclusion | ImmunityBio Advances NMIBC Program with Positive ANKTIVA® Data

Health / Cancer Treatment

ImmunityBio's Anktiva: Asian Expansion and NCCN Guideline Inclusion

ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) is making significant strides in bladder cancer treatment. Recently, it secured approval in Macau, marking its expansion into Asia, and was added to the National Comprehensive Cancer...

ImmunityBio (IBRX) Soars 11% as Asian Expansion Looms
ImmunityBio's Anktiva: Asian Expansion and NCCN Guideline Inclusion Image via Yahoo Finance
TOPIC ibrx stock

Health / Cancer Treatment

ImmunityBio Advances NMIBC Program with Positive ANKTIVA® Data

ImmunityBio (IBRX) is making significant strides in the treatment of non-muscle-invasive bladder cancer (NMIBC). Recent data highlights the effectiveness of ANKTIVA® when combined with Bacillus Calmette-Guérin (BCG) in BCG-naive patients. E...

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG